
Oncology NEWS International
- Oncology NEWS International Vol 15 No 9
- Volume 15
- Issue 9
Exjade Gains Approval in EU
The European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.
BASEL, SwitzerlandThe European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.
Articles in this issue
almost 20 years ago
President's Cancer Panel Assesses Progress in Two Areasalmost 20 years ago
Proposed Medicare OPPS Rule Draws Fire for Its 'Inadequate Reimbursement'almost 20 years ago
Cognitive Rx Reduces Depression in Breast Ca Ptsalmost 20 years ago
Nurses Develop Evidence-Based Guidelines for Mucositisalmost 20 years ago
Anastrozole Therapy for Breast Cancer Affects Bone Healthalmost 20 years ago
Is Demand for Trial Subjects Outpacing Supply?almost 20 years ago
Postchemo Disappearance of Liver Mets Doesn't Mean Curealmost 20 years ago
Aromasin-Related Bone Loss Affected by Vitamin D Levelsalmost 20 years ago
Melanoma Mets Regress After Gene Therapy












































































